Epidemic of Mucormycosis in COVID-19 Pandemic: A Position Paper.

Kulkarni, Rahul; Misra, Usha K; Meshram, Chandrashekhar; Kochar, Dhanpat; Modi, Manish; Vishnu, Venugopalan Y; Garg, Ravindra K; Surya, Nirmal

Kulkarni, Rahul; Misra, Usha K; Meshram, Chandrashekhar; Kochar, Dhanpat; Modi, Manish; Vishnu, Venugopalan Y; Garg, Ravindra K; Surya, Nirmal.

Kulkarni R; Department of Neurology, Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India.
Misra UK; Department of Neurosciences, Apollomedics Super Specialty Hospital, Lucknow, India.
Meshram C; Brain and Mind Institute, Nagpur, Maharashtra, India.
Kochar D; In-charge: Cerebral Malaria Research Centre, Sardar Patel Medical College and Associated Group of Hospitals, Bikaner, India.
Modi M; Department of Neurology, PGIMER, Chandigarh, India.
Vishnu VY; Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
Garg RK; Department of Neurology, King George Medical University, Lucknow, India.
Surya N; Chair, Tropical Neurology Subsection, Indian Academy of Neurology, Surya Neuro Centre, Mumbai, Maharashtra, India.

Ann Indian Acad Neurol ; 25(1): 7-10, 2022.

Article in English | MEDLINE | ID: covidwho-1726287

ABSTRACT

ABSTRACT

During the second wave of COVID-19 pandemic, there is a sudden increase in number of cases mucormycosis infection in India. This communication by the Tropical Neurology subsection expert group of the Indian Academy of Neurology (IAN) describes the clinical and diagnostic features, treatment of the disease and gives recommendations about the ways forward.

Keywords

COVID-19; Mucormycosis; rhino-orbito-cerebral syndrome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Ann Indian Acad Neurol Year: 2022 Document Type: Article Affiliation country: Aian.AIAN_421_21

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google